Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 1.00 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.63 |
| ▸ | FDPS | P14324 | 11/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533943 | 0.98 | LPAR1 (0.96) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL1533877 | 0.91 | LPAR1 (0.83) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL17476332 | 0.83 | LPAR1 (0.70) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL160868 | 0.81 | LPAR1 (0.68) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL21101672 | 0.81 | LPAR1 (0.68) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL6427229 | 0.81 | LPAR1 (0.68) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL21835985 | 0.80 | LPAR1 (0.67) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL9110451 | 0.78 | LPAR1 (0.64) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL21101802 | 0.77 | GGPS1 (0.68) | LPAR1LPAR3GGPS1FDPSSMPD1 | |
| SCHEMBL18114319 | 0.77 | GGPS1 (0.68) | LPAR1LPAR3GGPS1FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | claimed |
| JP-2007508324-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | claimed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | claimed |
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | MILLER DUANE D (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2262371-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | Rxbio, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010051053-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | disclosed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR1 1/4885LPAR3 6/4885GGPS1 832/4885 |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885GGPS1 1306/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | LPAR1 1/4885LPAR3 6/4885GGPS1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.